PE20170438A1 - Inhibidores espirociclicos de catepsina c - Google Patents
Inhibidores espirociclicos de catepsina cInfo
- Publication number
- PE20170438A1 PE20170438A1 PE2017000400A PE2017000400A PE20170438A1 PE 20170438 A1 PE20170438 A1 PE 20170438A1 PE 2017000400 A PE2017000400 A PE 2017000400A PE 2017000400 A PE2017000400 A PE 2017000400A PE 20170438 A1 PE20170438 A1 PE 20170438A1
- Authority
- PE
- Peru
- Prior art keywords
- catepsin
- compounds
- inhibitors
- oxetan
- heptan
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000003902 Cathepsin C Human genes 0.000 abstract 2
- 108090000267 Cathepsin C Proteins 0.000 abstract 2
- VIDWRXWIFCHQDH-HQGMYGGFSA-N C(#N)[C@H](CC1=C(C=C(C=C1)C1=CC2=C(C=N1)COC21CCN(CC1)C1COC1)F)NC(=O)[C@@H]1[C@H]2CC[C@@H](N1)C2 Chemical compound C(#N)[C@H](CC1=C(C=C(C=C1)C1=CC2=C(C=N1)COC21CCN(CC1)C1COC1)F)NC(=O)[C@@H]1[C@H]2CC[C@@H](N1)C2 VIDWRXWIFCHQDH-HQGMYGGFSA-N 0.000 abstract 1
- MIBKKDLVBYJWTB-AIKBEYBBSA-N C(#N)[C@H](CC1=C(C=C(C=C1)C=1C=C2C(=CC=1)COC21CCN(CC1)C1COC1)F)NC(=O)[C@@H]1[C@H]2CC[C@@H](N1)C2 Chemical compound C(#N)[C@H](CC1=C(C=C(C=C1)C=1C=C2C(=CC=1)COC21CCN(CC1)C1COC1)F)NC(=O)[C@@H]1[C@H]2CC[C@@H](N1)C2 MIBKKDLVBYJWTB-AIKBEYBBSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14184613 | 2014-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170438A1 true PE20170438A1 (es) | 2017-04-28 |
Family
ID=51535355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000400A PE20170438A1 (es) | 2014-09-12 | 2015-09-08 | Inhibidores espirociclicos de catepsina c |
Country Status (34)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9018227B2 (en) | 2010-03-19 | 2015-04-28 | Indiana State University | Nicotinic acetylcholine receptor agonists |
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| JP6529575B2 (ja) * | 2014-08-01 | 2019-06-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用 |
| RS59444B1 (sr) | 2014-09-12 | 2019-11-29 | Boehringer Ingelheim Int | Spirociklični inhibitori katepsina c |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2018162312A1 (en) * | 2017-03-10 | 2018-09-13 | Basf Se | Spirocyclic derivatives |
| US20190247400A1 (en) * | 2018-02-07 | 2019-08-15 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating granulomatosis with polyangiitis |
| US12059424B2 (en) | 2018-03-01 | 2024-08-13 | Astrazeneca Ab | Pharmaceutical compositions comprising (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
| AU2019306532A1 (en) | 2018-07-17 | 2021-03-04 | Insmed Incorporated | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis |
| CN110256429B (zh) * | 2019-06-17 | 2021-06-22 | 广东药科大学 | 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用 |
| CN110257504A (zh) * | 2019-06-30 | 2019-09-20 | 中南大学 | 一种难治性哮喘检测标记物的筛选方法及其应用 |
| WO2022020245A1 (en) | 2020-07-20 | 2022-01-27 | Insmed, Inc. | Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions |
| CN114106005B (zh) * | 2020-08-26 | 2025-08-01 | 西藏海思科制药有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| MX2023005589A (es) * | 2020-11-17 | 2023-07-31 | Vertex Pharma | Formas sólidas de ácido 4-(5-(4-fluorofenil)-6-(tetrahidro-2h-pira n-4-il)-1,5-dihidropirrolo[2,3-f]indazol-7-il)benzoico. |
| CN114591315A (zh) * | 2020-12-04 | 2022-06-07 | 瑞石生物医药有限公司 | 一种组织蛋白酶c小分子抑制剂 |
| WO2022117059A1 (zh) * | 2020-12-04 | 2022-06-09 | 瑞石生物医药有限公司 | 组织蛋白酶c小分子抑制剂及其医药用途 |
| JPWO2023243601A1 (enExample) * | 2022-06-13 | 2023-12-21 | ||
| EP4551554A1 (en) | 2022-07-06 | 2025-05-14 | Chiesi Farmaceutici S.p.A. | Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors |
| WO2024088307A1 (zh) * | 2022-10-26 | 2024-05-02 | 上海壹迪生物技术有限公司 | 一种新型肽基腈类化合物及其应用 |
| WO2024148308A1 (en) | 2023-01-06 | 2024-07-11 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2025214464A1 (en) * | 2024-04-12 | 2025-10-16 | Insmed Incorporated | Crystalline forms of (s) -n- (1-cyano-2- (2-fluoro-4- (1' - (oxetan-3-yl) -3h-spiro [isobenzofuran-1, 4' -piperidin] -6-yl) phenyl) ethyl) -2-azabicyclo [2.2.2] octane-1-carboxamide |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4125727A (en) | 1976-10-18 | 1978-11-14 | American Cyanamid Company | Method of preparing imidazoisoindolediones |
| GB8922355D0 (en) | 1989-10-04 | 1989-11-22 | British Telecomm | Sealing gland |
| GEP20012487B (en) | 1998-09-16 | 2001-07-25 | Merab Lomia | Use of Chemical Agent 5-carbarnoyl-5H-Dibenz (b,f) azepin, its Derivatives and Analogues by New Purpose |
| US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| AU2002254099B2 (en) | 2001-03-02 | 2006-07-06 | Axys Pharmaceuticals, Inc. | Cathepsin cysteine protease inhibitors |
| TW200306189A (en) | 2002-03-21 | 2003-11-16 | Merz Pharma Gmbh & Co Kgaa | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| US20070099958A1 (en) | 2003-06-18 | 2007-05-03 | Prozymex A/S | Protease inhibitors |
| TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
| WO2006096807A1 (en) | 2005-03-08 | 2006-09-14 | Janssen Pharmaceutica N.V. | Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists |
| SI2032535T1 (sl) * | 2006-06-01 | 2012-12-31 | Sanofi | Spirociklični nitrili kot proteazni inhibitorji |
| CA2664358A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diarylketimine derivative |
| WO2009047829A1 (ja) | 2007-10-12 | 2009-04-16 | Fujitsu Limited | Ｉｐ電話自動試験システム及び方法 |
| WO2009074829A1 (en) | 2007-12-12 | 2009-06-18 | Astrazeneca Ab | Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors |
| JP2012526093A (ja) | 2009-05-07 | 2012-10-25 | アストラゼネカ・アクチエボラーグ | 置換１−シアノエチルヘテロシクリルカルボキサミド化合物７５０ |
| WO2010142985A1 (en) | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
| WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
| US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| UY34765A (es) | 2012-04-27 | 2013-11-29 | Glaxo Group Ltd | Compuestos novedosos. |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| JP6038297B2 (ja) | 2012-05-22 | 2016-12-07 | ジェネンテック， インコーポレイテッド | Ｎ−置換ベンズアミドおよび疼痛の処置におけるそれらの使用 |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| EA030253B1 (ru) | 2012-09-28 | 2018-07-31 | Кэнсэр Ресерч Текнолоджи Лимитед | Азахиназолиновые ингибиторы атипичной протеинкиназы c |
| WO2014056942A1 (en) * | 2012-10-09 | 2014-04-17 | Boehringer Ingelheim International Gmbh | Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets |
| US10092572B2 (en) | 2012-10-15 | 2018-10-09 | Epizyme, Inc. | Substituted benzene compounds |
| AU2013331496B2 (en) | 2012-10-16 | 2017-07-27 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ROR-gamma-t |
| PE20151141A1 (es) | 2012-11-01 | 2015-08-06 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de jak |
| SMT201800230T1 (it) | 2012-12-21 | 2018-07-17 | Plexxikon Inc | Composti e metodi per la modulazione della chinasi e loro indicazioni |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| CN105026372B (zh) | 2012-12-21 | 2018-06-05 | 赛尔基因昆蒂赛尔研究公司 | 组蛋白脱甲基酶抑制剂 |
| US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
| MX363936B (es) | 2013-03-14 | 2019-04-09 | Boehringer Ingelheim Int | (bencil-ciano-metil)-amidas del acido 2-aza-biciclo[2.2.1]heptano- 3-carboxilico sustituidas como inhibidores de catepsina c. |
| CA2903979A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
| WO2014140091A1 (en) * | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調節劑 |
| JO3383B1 (ar) | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
| MA38493B1 (fr) | 2013-03-14 | 2017-10-31 | Newlink Genetics Corp | Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane |
| JP6330058B2 (ja) * | 2014-04-29 | 2018-05-23 | ケアベイ・ヨーロッパ・リミテッドＣａｒｅｂａｙ Ｅｕｒｏｐｅ Ｌｉｍｉｔｅｄ | 針の挿入深さを調節する装置 |
| EP3164272A1 (en) | 2014-07-03 | 2017-05-10 | Bridgestone Americas Tire Operations, LLC | Sidewall decoration on rim guard |
| ES2705623T3 (es) | 2014-09-12 | 2019-03-26 | Glaxosmithkline Ip No 2 Ltd | Derivados de tetrahidroquinolina como inhibidores del bromodominio |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| TW201625591A (zh) | 2014-09-12 | 2016-07-16 | 美國禮來大藥廠 | 吖丁啶基氧苯基吡咯啶化合物 |
| RS59444B1 (sr) * | 2014-09-12 | 2019-11-29 | Boehringer Ingelheim Int | Spirociklični inhibitori katepsina c |
-
2015
- 2015-09-08 RS RSP20191350 patent/RS59444B1/sr unknown
- 2015-09-08 SI SI201530977T patent/SI3191487T1/sl unknown
- 2015-09-08 LT LTEP15757523.4T patent/LT3191487T/lt unknown
- 2015-09-08 CN CN201580048467.6A patent/CN107074870B/zh active Active
- 2015-09-08 EA EA201790576A patent/EA031376B1/ru not_active IP Right Cessation
- 2015-09-08 ES ES15757523T patent/ES2749009T3/es active Active
- 2015-09-08 MX MX2019009695A patent/MX378099B/es unknown
- 2015-09-08 KR KR1020177009993A patent/KR102510588B1/ko active Active
- 2015-09-08 DK DK15757523T patent/DK3191487T3/da active
- 2015-09-08 HU HUE15757523A patent/HUE047208T2/hu unknown
- 2015-09-08 MY MYPI2017000213A patent/MY188382A/en unknown
- 2015-09-08 SG SG11201701633SA patent/SG11201701633SA/en unknown
- 2015-09-08 UA UAA201703350A patent/UA118610C2/uk unknown
- 2015-09-08 EP EP19155235.5A patent/EP3511331A1/en not_active Withdrawn
- 2015-09-08 WO PCT/EP2015/070449 patent/WO2016038007A1/en not_active Ceased
- 2015-09-08 PL PL15757523T patent/PL3191487T3/pl unknown
- 2015-09-08 PE PE2017000400A patent/PE20170438A1/es unknown
- 2015-09-08 NZ NZ728684A patent/NZ728684A/en unknown
- 2015-09-08 EP EP15757523.4A patent/EP3191487B1/en active Active
- 2015-09-08 AU AU2015314355A patent/AU2015314355B2/en active Active
- 2015-09-08 CA CA2960916A patent/CA2960916C/en active Active
- 2015-09-08 PT PT157575234T patent/PT3191487T/pt unknown
- 2015-09-08 MX MX2017003156A patent/MX367316B/es active IP Right Grant
- 2015-09-08 BR BR112017003433-6A patent/BR112017003433B1/pt active IP Right Grant
- 2015-09-08 HR HRP20191756TT patent/HRP20191756T1/hr unknown
- 2015-09-08 AP AP2017009733A patent/AP2017009733A0/en unknown
- 2015-09-08 JP JP2017513658A patent/JP2017526716A/ja not_active Ceased
- 2015-09-08 CN CN201810030066.3A patent/CN108047240B/zh active Active
- 2015-09-10 US US14/849,710 patent/US9540373B2/en not_active Ceased
- 2015-09-11 TW TW104130165A patent/TWI687424B/zh active
-
2016
- 2016-11-29 US US15/362,949 patent/US9879026B2/en active Active
-
2017
- 2017-01-24 IL IL250262A patent/IL250262B/en active IP Right Grant
- 2017-02-23 CL CL2017000432A patent/CL2017000432A1/es unknown
- 2017-03-07 CO CONC2017/0002268A patent/CO2017002268A2/es unknown
- 2017-03-09 SA SA517381064A patent/SA517381064B1/ar unknown
- 2017-03-10 PH PH12017500453A patent/PH12017500453B1/en unknown
- 2017-11-30 US US15/827,433 patent/USRE47636E1/en active Active
- 2017-12-22 JP JP2017246001A patent/JP6360961B2/ja active Active
-
2018
- 2018-11-14 HK HK18114501.3A patent/HK1255362A1/zh unknown
-
2019
- 2019-11-06 CY CY20191101154T patent/CY1123033T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170438A1 (es) | Inhibidores espirociclicos de catepsina c | |
| CO7310529A2 (es) | Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano rory | |
| CL2018000292A1 (es) | Compuestos farmacéuticos | |
| PE20161251A1 (es) | Compuestos heteroarilo o arilo biciclicos fusionados y su uso como inhibidores de irak4 | |
| PE20151605A1 (es) | Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y analogos de los mismos como inhibidores de autotaxina | |
| NZ702539A (en) | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] | |
| PE20151982A1 (es) | Derivados de bencimidazolona como inhibidores del bromodominio | |
| EA202190619A1 (ru) | Противовирусные соединения | |
| UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
| UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| EA201100161A1 (ru) | Производные хинуклидина карбоната и их медицинские композиции | |
| CR20150057A (es) | Antagonistas del receptor de 5-ht3 | |
| PE20151892A1 (es) | Compuestos tetraciclicos sustituidos con heterociclo y metodos de uso de los mismos para el tratamiento de enfermedades viricas | |
| UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
| EA201170997A1 (ru) | Производные индола в качестве противораковых агентов | |
| UY35338A (es) | Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen | |
| PH12018500378B1 (en) | Novel annelated phenoxyacetamides | |
| PE20170294A1 (es) | Inhibidores de aldosterona sintasa | |
| DK2257526T3 (da) | Spiro(5,5)undecan-derivater | |
| EA201491251A1 (ru) | Соединение 2-(пиридин-2-ил)-1,7-диазаспиро[4.4]нонан-6-она в качестве модуляторов потенциалзависимых натриевых каналов | |
| CL2018000856A1 (es) | Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida. | |
| EA201591023A1 (ru) | Твердая форма производного дигидропиридооксазина | |
| ECSP15007708A (es) | Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano ror[gamma] | |
| ECSP14033496A (es) | Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huérfano ror[gamma] |